Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 27-34

  Schiavon, Angélica Pupin ^a   Bonato, Jéssica Mendes ^a   Milani, Humberto ^a   Guimarães, Francisco Silveira ^b   Weffort de Oliveira, Rúbia Maria ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressant; Cannabidiol; Neurogenesis; Subgranular zone; Subventricular zone; Swiss mice

Indexed keywords

BROXURIDINE; CANNABIDIOL; DOUBLECORTIN; IMIPRAMINE; KI 67 ANTIGEN; DOUBLECORTIN PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MKI67 PROTEIN, MOUSE; NEUROPEPTIDE; PSYCHOTROPIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DENTATE GYRUS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELEVATED PLUS MAZE TEST; EMOTION; HIPPOCAMPUS; IMMOBILITY; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SUBVENTRICULAR ZONE; SWISS WEBSTER MOUSE; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; DRUG EFFECTS; DRUG THERAPY; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; STEM CELL NICHE;

ANIMALS; ANXIETY; CANNABIDIOL; CELL PROLIFERATION; DENTATE GYRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; IMIPRAMINE; KI-67 ANTIGEN; MALE; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MOTOR ACTIVITY; NEUROGENESIS; NEUROPEPTIDES; PSYCHOTROPIC DRUGS; RANDOM ALLOCATION; STEM CELL NICHE;

EID: 84937057203     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.06.017     Document Type: Article

References (75)

1. Balu D.T., Lucki I. Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology. Neurosci. Biobehav. 2009, 33(3):232-252.
2. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 2007, 27(43):11700-11711.
3. Benninghoff J., Grunze H., Schindler C., Genius J., Schloesser R.J., van der Ven A., Dehning S., Wiltfang J., Möller H.J., Rujescu D. Ziprasidone-not haloperidol-induces more de-novo neurogenesis of adult neural stem cells derived from murine hippocampus. Pharmacopsychiatry 2013, 46(1):10-15.
4. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134:845-852.
5. Campos A.C., Guimarães F.S. Involvement of 5-HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berlin) 2008, 199(2):223-230.
6. Campos A.C., Guimarães F.S. Activation of 5-HT1A receptors mediates the anxiolytic effects of cannabidiol in a PTSD model. Behav. Pharmacol. 2009, 20:S54.
7. Campos A.C., Moreira F.A., Gomes F.V., Del Bel E.A., Guimarães F.S. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos. Trans. R. Soc. B 2012, 367:3364-3378.
8. Campos A.C., Ortega Z., Palazuelos J., Fogaça M.V., Aguiar D.C., Díaz-Alonso J., Ortega-Gutiérrez S., Vázquez-Villa H., Moreira F.A., Guzmán M., Galve-Roperh I., Guimarães F.S. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int. J. Neuropsychopharmacol. 2013, 16(6):1407-1419.
9. Casarotto P.C., Gomes F.V., Resstel L.B., Guimarães F.S. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav. Pharmacol. 2010, 21(4):353-358.
10. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 2000, 75(4):1729-1734.
11. Cheng D., Low J.K., Logge W., Garner B., Karl T. Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1{increment}E9 mice. Psychopharmacology (Berlin) 2014, 231(15):3009-3017.
12. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Ver. 2005, 29(4-5):571-625.
13. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., Drew M., Craig D.A., Guiard B.P., Guilloux J.P., Artymyshyn R.P., Gardier A.M., Gerald C., Antonijevic I.A., Leonardo E.D., Hen R. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62(4):479-493.
14. Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., Platt B., Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berlin) 2012, 219(3):859-873.
15. Denis-Donini S., Dellarole A., Crociara P., Francese M.T., Bortolotto V., Quadrato G., Canonico P.L., Orsetti M., Ghi P., Memo M., Bonini S.A., Ferrari-Toninelli G., Grilli M. Impaired adult neurogenesis associated with short-term memory defects in NF-kappaB p50-deficient mice. J. Neurosci. 2008, 9(15):3911-3919.
16. Diniz L., dos Santos T.B., Britto L.R., Céspedes I.C., Garcia M.C., Spadari-Bratfisch R.C., Medalha C.C., de Castro G.M., Montesano F.T., Viana M.B. Effects of chronic treatment with corticosterone and imipramine on fos immunoreactivity and adult hippocampal neurogenesis. Behav. Brain Res. 2013, 238:170-177.
17. Doetsch F., Caillé I., Lim D.A., García-Verdugo J.M., Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999, 97(6):703-716.
18. Eisch A.J., Barrot M., Schad C.A., Self D.W., Nestler E.J. Opiates inhibit neurogenesis in the adult rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(13):7579-7584.
19. El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav. 2010, 95(4):434-442.
20. ElBatsh M.M., Assareh N., Marsden C.A., Kendall D.A. Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berlin) 2012, 221(2):239-247.
21. Fenton E.Y., Fournier N.M., Lussier A.L., Romay-Tallon R., Caruncho H.J., Kalynchuk L.E. Imipramine protects against the deleterious effects of chronic corticosterone on depression-like behavior, hippocampal reelin expression, and neuronal maturation. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 60C:52-59.
22. Fogaça M.V., Sonego A.B., Rioli V., Gozzo F.C., Dale C.S., Ferro E.S., Guimarães F.S. Anxiogenic-like effects induced by hemopressin in rats. Pharmacol. Biochem. Behav. 2015, 129:7-13.
23. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego. 2 ed.
24. Gomes F.V., Resstel L.B., Guimarães F.S. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berlin) 2011, 213(2-3):465-4.
25. Gomes F.V., Llorente R., Del Bel E.A., Viveros M.P., López-Gallardo M., Guimarães F.S. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr. Res. 2015, 10.1016/j.schres.2015.01.015.
26. Gururajan A., Taylor D.A., Malone D.T. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behav. Brain Res. 2011, 222(2):299-308.
27. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004, 29(6):1063-1069.
28. Han X., Tong J., Zhang J., Farahvar A., Wang E., Yang J., Samadani U., Smith D.H., Huang J.H. Imipramine treatment improves cognitive outcome associated with enhanced hippocampalneurogenesis after traumatic brain injury in mice. J. Neurotrauma 2011, 28(6):995-1007.
29. Hitoshi S., Maruta N., Higashi M., Kumar A., Kato N., Ikenaka K. Antidepressant drugs reverse the loss of adult neural stem cells following chronic stress. J. Neurosci. Res. 2007, 85(16):3574-3585.
30. Holick K.A., Lee D.C., Hen R., Dulawa S.C. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 2008, 33(2):406-417.
31. Huang G.J., Bannerman D., Flint J. Chronic fluoxetine treatment alters behavior, but not adult hippocampal neurogenesis in BALB/cJmice. Mol. Psychiatry 2008, 13(2):119-121.
32. Jun H., Mohammed Qasim Hussaini S., Rigby M.J., Jang M.H. Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders. Neural Plast. 2012, 1(1):41-51.
33. Kang K., Kim Y.J., Lee S.H., Yoon B.W. Lithium fails to enhance neurogenesis in subventricular zone and dentate subgranular zone after intracerebral hemorrhage in rats. Neurol. Res. 2014, 36(1):79-85.
34. Keilhoff G., Becker A., Grecksch G., Bernstein H.G., Wolf G. Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 2006, 31(6):1165-1176.
35. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry 2004, 56(8):570-580.
36. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 2005, 19(1-2):96-107.
37. Lee S., Kim D.H., Yoon S.H., Ryu J.H. Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus. Neurosci. Lett. 2009, 467(2):111-116.
38. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., Klosterkötter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transcult. Psychiatry 2012, 20:e94.
39. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin) 1987, 92(2):180-185.
40. Llorens-Martin M., Torres-Aleman I., Trejo J.L. Pronounced individual variation in the response to the stimulatory action of exercise on immature hippocampal neurons. Hippocampus 2006, 16:480-490.
41. Lois C., Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(5):2074-2077.
42. Long L.E., Malone D.T., Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006, 31(4):795-803.
43. Long L.E., Chesworth R., Huang X.F., McGregor I.S., Arnold J.C., Karl T. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int. J. Neuropsychopharmacol. 2010, 13(7):861-876.
44. Lucassen P.J., Stumpel M.W., Wang Q., Aronica E. Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients. Neuropharmacology 2010, 58(6):940-949.
45. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20(24):9104-9110.
46. Manev R., Uz T., Manev H. Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus. Eur. J. Pharmacol. 2001, 420(2-3):R1-R2.
47. Moreira F.A., Aguiar D.C., Guimarães F.S. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(8):1466-1471.
48. Parent J.M. Injury-induced neurogenesis in the adult mammalian brain. Neuroscientist 2003, 9:261-272.
49. Patrício P., Mateus-Pinheiro A., Sousa N., Pinto L. Re-cycling paradigms: cell cycle regulation in adult hippocampal neurogenesis and implications for depression. Mol. Neurobiol. 2013, 48:84-96.
50. Pazos M.R., Cinquina V., Gómez A., Layunta R., Santos M., Fernández-Ruiz J., Martínez-Orgado J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 2012, 63(5):776-783.
51. Pechnick R.N., Zonis S., Wawrowsky K., Cosgayon R., Farrokhi C., Lacayo L., Chesnokova V. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hippocampus. PLoS One 2011, 6(11):e27290.
52. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 1986, 24(3):525-529.
53. Peng Z., Zhang R., Wang H., Chen Y., Xue F., Wang L., Yang F., Chen Y., Liu L., Kuang F., Tan Q. Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells. Behav. Brain Res. 2013, 244:1-8.
54. Possamai F., Dos Santos J., Walber T., Marcon J.C., Dos Santos T.S., Lino de Oliveira C. Influence of enrichment on behavioral and neurogenic effects of antidepressants in Wistar rats submitted to repeated forced swim test. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 58:15-21.
55. Resstel L.B., Joca S.R., Moreira F.A., Corrêa F.M., Guimarães F.S. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav. Brain Res. 2006, 172(2):294-298.
56. Resstel L.B., Tavares R.F., Lisboa S.F., Joca S.R., Corrêa F.M., Guimarães F.S. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br. J. Pharmacol. 2009, 156(1):181-188.
57. Réus G.Z., Stringari R.B., Ribeiro K.F., Luft T., Abelaira H.M., Fries G.R., Aguiar B.W., Kapczinski F., Hallak J.E., Zuardi A.W., Crippa J.A., Quevedo J. Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatr. 2011, 23(5):241-248.
58. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 2005, 30(8):1037-1043.
59. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
60. Saravia F., Beauquis J., Pietranera L., De Nicola A.F. Neuroprotective effects of estradiol in hippocampal neurons and glia of middle age mice. Psychoneuroendocrinology 2007, 32(5):480-492.
61. Schiavon A.P., Milani H., Romanini C.V., Foresti M.L., Castro O.W., Garcia-Cairasco N., de Oliveira R.M. Imipramine enhances cell proliferation and decreases neurodegeneration in the hippocampus after transient global cerebral ischemia in rats. Neurosci. Lett. 2010, 470(1):43-48.
62. Schiavon A.P., Soares L.M., Bonato J.M., Milani H., Guimarães F.S., Weffort de Oliveira R.M. Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox. Res. 2014, 26(4):307-316.
63. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., Nguyen P.T., Ramesh D., Booker L., Burston J.J., Thomas E.A., Selley D.E., Sim-Selley L.J., Liu Q.S., Lichtman A.H., Cravatt B.F. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 2010, 13(9):1113-1119.
64. Steru L., Chermat R., Thierry B., Simon P., Porsolt R. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
65. Surget A., Saxe M., Leman S., Ibarguen-Vargas Y., Chalon S., Griebel G., Hen R., Belzung C. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol. Psychiatry 2008, 64(4):293-301.
66. Suyama S., Sunabori T., Kanki H., Sawamoto K., Gachet C., Koizumi S., et al. Purinergic signaling promotes proliferation of adult mouse subventricular zone cells. J. Neurosci. 2012, 32(27):9238-9247.
67. van Praag H., Christie B.R., Sejnowski T.J., Gage F.H. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(23):13427-13431.
68. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002, 69(1):72-79.
69. Wolf S.A., Bick-Sander A., Fabel K., Leal-Galicia P., Tauber S., Ramirez-Rodriguez G., Müller A., Melnik A., Waltinger T.P., Ullrich O., Kempermann G. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun. Signal. 2010, 8:12. (Jun 17).
70. Zanelati T.V., Biojone C., Moreira F.A., Guimarães F.S., Joca S.R. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br. J. Pharmacol. 2010, 159(1):122-128.
71. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology (Berlin) 1982, 76(3):245-250.
72. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berlin) 1991, 104(2):260-264.
73. Zuardi A.W., Cosme R.A., Graeff F.G., Guimarães F.S. Effects of ipsapirone and cannabidiol on human experimental anxiety. J. Psychopharmacol. 1993, 7(1 Suppl.):82-88.
74. Zuardi A.W., Morais S.L., Guimarães F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56(10):485-486.
75. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., Crippa J.A. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 2006, 20(5):683-686.